AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Axsome Therapeutics has acquired AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator licensed from AstraZeneca, to treat epilepsy. AZD7325 has completed Phase 1 trials and demonstrated anti-convulsant effects in preclinical seizure models. Axsome plans to begin Phase 2 trial-enabling activities in 2026 and has acquired Baergic Bio, Inc. to receive worldwide commercial, development, and manufacturing rights to AZD7325.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet